BMS-182874

BMS-182874 is a **selective endothelin receptor type A (ETA) antagonist** classified as a small molecule drug. It was developed by Bristol Myers Squibb for cardiovascular diseases, with primary investigation for conditions such as hypertension and hyperproliferative vascular diseases. The drug functions by blocking ETA receptors, thereby inhibiting endothelin-1-mediated vasoconstriction and smooth muscle cell proliferation, processes implicated in diseases like restenosis. Studies show it reduces intimal lesion formation following vascular injury and offers renoprotective effects in diabetic nephropathy models, possibly through inhibition of the renin-angiotensin-aldosterone system and reactivation of NO synthesis[1][3]. Preclinical data also indicate it may enhance analgesic effects via imidazoline I2 receptor-mediated mechanisms[1].

Other names

BMS182874BMS-182874BMS 182874